Roche: takeover bid for Poseida Therapeutics
(CercleFinance.com) - Roche announces the launch of its tender offer for all outstanding common shares of Poseida Therapeutics, in accordance with the combination agreement announced on 25 November.
The tender offer is for nine dollars per Poseida share in cash, plus a CVR to receive certain contingent payments of up to four dollars per share in cash. The offer period will expire on the evening of 7 January, unless extended.
Completion of the tender offer is subject to customary conditions, including receipt of required regulatory approvals, as well as the valid tender of a majority of Poseida's outstanding common shares.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The tender offer is for nine dollars per Poseida share in cash, plus a CVR to receive certain contingent payments of up to four dollars per share in cash. The offer period will expire on the evening of 7 January, unless extended.
Completion of the tender offer is subject to customary conditions, including receipt of required regulatory approvals, as well as the valid tender of a majority of Poseida's outstanding common shares.
Copyright (c) 2024 CercleFinance.com. All rights reserved.